

REMARKS

Claim 46 has been amended to specify that the method of treatment is for a human. Although the term "human" is not expressly recited in the specification, it would be inherently obvious to one of ordinary skill in the art that the method is directed to human treatment, in view of the description of the various diseases to be treated, such as recited on pages 84-86 of the specification.

In view of the foregoing amendment, the rejection of claim 46 is deemed to be overcome.

Other minor changes have been effected to the claims which are self-explanatory.

There is submitted herewith a terminal disclaimer in conformance with U.S. practice.

The rejection of claims 1-6, 9-14, 16-17, 19-20, 23, 25, 28, 30, 33, 36-37, 40, 42 and 44-47 under the judicially created doctrine of obviousness-type double patenting is thus deemed to be overcome.

In view of the foregoing, it is believed that each ground of rejection set forth in the Official Action has been overcome, and that the application is now in condition for allowance. Accordingly, such allowance is solicited.

Respectfully submitted,

Takehiro FUKAMI et al.

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

By: Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/kes
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
April 15, 2004